Japan’s Pharmaceuticals And Medical Devices Agency Issues Regulatory Approval To Natera's Signatera Test

This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in Japan in the first half of 2027, following the PMDA’s approval of atezolizumab in MIBC.